Cargando…

Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry

BACKGROUND: First-line ablation for atrial fibrillation (AF) reduces the risk of recurrent atrial arrhythmias compared to medical therapy. However, the prognostic benefit of early AF ablation remains undetermined. Herein, we aimed to evaluate the effects of early AF ablation compared to medical ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Wern Yew, Calvert, Peter, Gupta, Dhiraj, Huisman, Menno V., Lip, Gregory Y. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424157/ https://www.ncbi.nlm.nih.gov/pubmed/35488127 http://dx.doi.org/10.1007/s00392-022-02022-1

Ejemplares similares

Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA‐AF Registry
por: Ding, Wern Yew, et al.
Publicado: (2022)

Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective GLORIA-AF Registry
por: Romiti, Giulio Francesco, et al.
Publicado: (2022)

Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA‐AF Phase III Registry
por: Bayer, Valentina, et al.
Publicado: (2022)

Stroke‐prevention strategies in North American patients with atrial fibrillation: The GLORIA‐AF registry program
por: McIntyre, William F., et al.
Publicado: (2018)

Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry
por: Mazurek, Michał, et al.
Publicado: (2017)

Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry
por: Ma, Changsheng, et al.
Publicado: (2020)

Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF
por: Kozieł, Monika, et al.
Publicado: (2021)

Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program
por: Beier, Lea, et al.
Publicado: (2022)

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
por: Huisman, Menno V., et al.
Publicado: (2022)

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
por: Lip, Gregory Y. H., et al.
Publicado: (2022)

Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry: Trends in antithrombotic therapy use in China
por: Liu, Xiaoxia, et al.
Publicado: (2023)

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
por: Lip, Gregory Y. H., et al.
Publicado: (2022)

Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up
por: Kozieł, Monika, et al.
Publicado: (2020)

Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry
por: Dubner, Sergio, et al.
Publicado: (2020)

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry
por: Romiti, Giulio Francesco, et al.
Publicado: (2023)

Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF
por: Dubner, Sergio J., et al.
Publicado: (2020)

Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF
por: van der Wall, Sake J., et al.
Publicado: (2021)

Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program
por: Azar, Rabih R., et al.
Publicado: (2021)

Impact of renal impairment on atrial fibrillation: ESC‐EHRA EORP‐AF Long‐Term General Registry
por: Ding, Wern Yew, et al.
Publicado: (2022)

Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort
por: Huisman, Menno V., et al.
Publicado: (2016)

Ablation index-guided 50W radiofrequency ablation for left atrial posterior wall isolation in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Feasibility of weight loss in obese atrial fibrillation patients attending a specialist arrhythmia clinic and its impact on ablation outcomes
por: Yew Ding, Wern, et al.
Publicado: (2020)

Relationship between Renal Function, Fibrin Clot Properties and Lipoproteins in Anticoagulated Patients with Atrial Fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies
por: Ding, Wern Yew, et al.
Publicado: (2020)

Short‐Term Outcomes in Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: How Important Is Ethnicity?
por: Ding, Wern Yew, et al.
Publicado: (2019)

Atrial fibrillation in obesity: Weighing up the evidence for catheter ablation
por: Javed, Saad, et al.
Publicado: (2020)

Contemporary management of atrial fibrillation and the predicted vs. absolute risk of ischaemic stroke despite treatment: a report from ESC-EHRA EORP-AF Long-Term General Registry
por: Ding, Wern Yew, et al.
Publicado: (2022)

Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion
por: Ding, Wern Yew, et al.
Publicado: (2020)

The neurocognitive effects of atrial fibrillation: benefits of the ABC pathway
por: Calvert, Peter, et al.
Publicado: (2023)

Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry
por: Romiti, Giulio Francesco, et al.
Publicado: (2022)

Silent cerebral lesions following catheter ablation for atrial fibrillation: a state-of-the-art review
por: Calvert, Peter, et al.
Publicado: (2023)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

ABC-AF-Stroke score predicts thromboembolism in non-anticoagulated patients following successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry
por: Wang, Yufeng, et al.
Publicado: (2023)

Indonesian registry on atrial fibrillation (OneAF)
por: Raharjo, Sunu Budhi, et al.
Publicado: (2021)

Predicting Heart Failure in Patients with Atrial Fibrillation: A Report from the Prospective COOL-AF Registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2023)

Catheter ablation for atrial fibrillation in heart failure: untying the Gordian knot
por: Javed, Saad, et al.
Publicado: (2021)

Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial
por: Shantsila, Eduard, et al.
Publicado: (2020)

Integrated Care for Atrial Fibrillation Using the ABC Pathway in the Prospective APHRS-AF Registry
por: Bucci, Tommaso, et al.
Publicado: (2023)

Procedural Trends in Catheter Ablation of Persistent Atrial Fibrillation: Insights From the Real-AF Registry
por: Sharma, Esseim, et al.
Publicado: (2023)

Relationship between lipoproteins, thrombosis, and atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tp7krsdgb7eqp0pvbq4172ol2g